China · Delayed Price · Currency is CNY Sirio Pharma Statistics
Total Valuation
Sirio Pharma has a market cap or net worth of CNY 5.15 billion. The enterprise value is 6.11 billion.
| Market Cap | 5.15B |
| Enterprise Value | 6.11B |
Important Dates
The last earnings date was Saturday, October 24, 2026.
| Earnings Date | Oct 24, 2026 |
| Ex-Dividend Date | Jun 5, 2026 |
Share Statistics
Sirio Pharma has 307.02 million shares outstanding. The number of shares has decreased by -1.38% in one year.
| Current Share Class | 307.02M |
| Shares Outstanding | 307.02M |
| Shares Change (YoY) | -1.38% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 20.70% |
| Owned by Institutions (%) | 15.68% |
| Float | 112.06M |
Valuation Ratios
The trailing PE ratio is 47.59 and the forward PE ratio is 14.68.
| PE Ratio | 47.59 |
| Forward PE | 14.68 |
| PS Ratio | 1.27 |
| PB Ratio | 1.67 |
| P/TBV Ratio | 2.29 |
| P/FCF Ratio | 53.54 |
| P/OCF Ratio | 10.98 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.07, with an EV/FCF ratio of 63.56.
| EV / Earnings | 57.49 |
| EV / Sales | 1.51 |
| EV / EBITDA | 14.07 |
| EV / EBIT | 29.17 |
| EV / FCF | 63.56 |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.64.
| Current Ratio | 1.06 |
| Quick Ratio | 0.75 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 4.53 |
| Debt / FCF | 20.45 |
| Interest Coverage | 1.90 |
Financial Efficiency
Return on equity (ROE) is 0.02% and return on invested capital (ROIC) is 5.16%.
| Return on Equity (ROE) | 0.02% |
| Return on Assets (ROA) | 2.19% |
| Return on Invested Capital (ROIC) | 5.16% |
| Return on Capital Employed (ROCE) | 5.70% |
| Weighted Average Cost of Capital (WACC) | 5.55% |
| Revenue Per Employee | 1.45M |
| Profits Per Employee | 38,231 |
| Employee Count | 2,776 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 4.90 |
Taxes
| Income Tax | -13.66M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.53% in the last 52 weeks. The beta is 0.31, so Sirio Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -27.53% |
| 50-Day Moving Average | 17.61 |
| 200-Day Moving Average | 19.26 |
| Relative Strength Index (RSI) | 37.10 |
| Average Volume (20 Days) | 1,784,963 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sirio Pharma had revenue of CNY 4.04 billion and earned 106.13 million in profits. Earnings per share was 0.35.
| Revenue | 4.04B |
| Gross Profit | 1.21B |
| Operating Income | 209.20M |
| Pretax Income | -12.94M |
| Net Income | 106.13M |
| EBITDA | 391.67M |
| EBIT | 209.20M |
| Earnings Per Share (EPS) | 0.35 |
Balance Sheet
The company has 990.73 million in cash and 1.96 billion in debt, with a net cash position of -972.47 million or -3.17 per share.
| Cash & Cash Equivalents | 990.73M |
| Total Debt | 1.96B |
| Net Cash | -972.47M |
| Net Cash Per Share | -3.17 |
| Equity (Book Value) | 3.08B |
| Book Value Per Share | 10.39 |
| Working Capital | 140.92M |
Cash Flow
In the last 12 months, operating cash flow was 468.22 million and capital expenditures -372.22 million, giving a free cash flow of 96.00 million.
| Operating Cash Flow | 468.22M |
| Capital Expenditures | -372.22M |
| Depreciation & Amortization | 182.47M |
| Net Borrowing | 434.14M |
| Free Cash Flow | 96.00M |
| FCF Per Share | 0.31 |
Margins
Gross margin is 29.89%, with operating and profit margins of 5.18% and 2.63%.
| Gross Margin | 29.89% |
| Operating Margin | 5.18% |
| Pretax Margin | -0.32% |
| Profit Margin | 2.63% |
| EBITDA Margin | 9.70% |
| EBIT Margin | 5.18% |
| FCF Margin | 2.38% |
Dividends & Yields
This stock pays an annual dividend of 0.13, which amounts to a dividend yield of 0.77%.
| Dividend Per Share | 0.13 |
| Dividend Yield | 0.77% |
| Dividend Growth (YoY) | -80.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 75.71% |
| FCF Payout Ratio | 25.65% |
| Buyback Yield | 1.38% |
| Shareholder Yield | 2.15% |
| Earnings Yield | 2.10% |
| FCF Yield | 1.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 27, 2025. It was a forward split with a ratio of 1.3.
| Last Split Date | May 27, 2025 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
Sirio Pharma has an Altman Z-Score of 2.48 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.48 |
| Piotroski F-Score | 5 |